- Home
- SKE vs NAMS Comparison
SKE vs NAMS Comparison
Compare SKE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKE | NAMS |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKE | NAMS |
|---|---|---|
| Price | $32.87 | $34.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $47.38 |
| AVG Volume (30 Days) | ★ 1.3M | 584.0K |
| Earning Date | 03-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $8.53 | $14.06 |
| 52 Week High | $35.69 | $42.00 |
Technical Indicators
Market Signals| Indicator | SKE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 56.04 |
| Support Level | $30.69 | $33.14 |
| Resistance Level | $34.49 | $35.61 |
| Average True Range (ATR) | 2.08 | 1.48 |
| MACD | -0.11 | 0.39 |
| Stochastic Oscillator | 67.89 | 81.39 |
Price Performance
Historical ComparisonAbout SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.